Certified by Founder
Lodge
Immunai
start up
United States
- New York, NY
- 28/10/2021
- Series B
- $215,000,000
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
- Industry Biotechnology Research
- Website https://www.immunai.com/
- LinkedIn https://www.linkedin.com/company/immunai/
Talvy | $2,000,000 | (Mar 11, 2026)
Unreasonable Labs | $13,500,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)